ESMO 2016 Congress
Copenhagen
Abstracts, slide sets and webcasts from ESMO 2016 are now available.
Neoadjuvant Osimertinib Shows ‘Promising Efficacy’ For EGFR-Mutated Resectable NSCLC
From the European Lung Cancer Congress 2022
Patients with stage II–IIIB N2 NSCLC and a relevant EGFR mutation may benefit from neoadjuvant osimertinib
NeoCOAST Points To Neoadjuvant Durvalumab Combination Potential For Early-Stage NSCLC
From the 2022 AACR Annual Meeting:
Combining neoadjuvant durvalumab with oleclumab, monalizumab or danvatirsen may offer novel strategies for early-stage NSCLC
HER3-DXd Induces CelTIL Increase In Early-Stage HR-Positive, HER2-Negative Breast Cancer
From ESMO Breast Cancer 2022:
A single dose of HER3-targeted antibody–drug conjugate induces a CelTIL response in treatment-naïve early-stage hormone receptor-positive, HER2-negative breast cancer
monarchE: 2-Year IDFS Benefit Confirmed For Clinicopathological High-Risk Breast Cancer Cohort
From ESMO Breast Cancer 2022:
Patients recruited to the monarchE trial on the basis of a high clinicopathological risk of early breast cancer recurrence derive a significant invasive disease-free survival benefit from abemaciclib use